Resonant Capital Advisors LLC Lowers Position in Johnson & Johnson $JNJ

Resonant Capital Advisors LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 41.0% during the first quarter, HoldingsChannel reports. The firm owned 19,429 shares of the company’s stock after selling 13,483 shares during the period. Resonant Capital Advisors LLC’s holdings in Johnson & Johnson were worth $4,749,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of JNJ. Northwest Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $202,000. Montz Harcus Wealth Management LLC raised its stake in Johnson & Johnson by 17.7% in the first quarter. Montz Harcus Wealth Management LLC now owns 1,618 shares of the company’s stock worth $396,000 after buying an additional 243 shares in the last quarter. Swedbank AB lifted its holdings in Johnson & Johnson by 27.3% during the first quarter. Swedbank AB now owns 2,921,146 shares of the company’s stock worth $714,045,000 after buying an additional 626,017 shares during the period. Integrated Advisors Network LLC lifted its holdings in Johnson & Johnson by 0.8% during the first quarter. Integrated Advisors Network LLC now owns 30,779 shares of the company’s stock worth $7,524,000 after buying an additional 237 shares during the period. Finally, Strata Wealth Advisors LLC boosted its position in Johnson & Johnson by 3.6% during the 1st quarter. Strata Wealth Advisors LLC now owns 3,681 shares of the company’s stock valued at $900,000 after acquiring an additional 128 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a new ablation catheter platform that could strengthen its electrophysiology business and help drive future growth. Article Title
• Positive Sentiment: Jim Cramer said Johnson & Johnson “will have lots of good news” about its blockbuster drugs, adding to bullish sentiment around the stock. Article Title
• Positive Sentiment: Zacks highlighted JNJ’s strong earnings surprise history and said the company has the ingredients to beat estimates again in its next quarterly report, reinforcing confidence ahead of earnings. Article Title
• Positive Sentiment: TipRanks included Johnson & Johnson among Dividend Aristocrat stocks with a “Strong Buy” rating from top analysts, which may support demand for the shares. Article Title
• Neutral Sentiment: Several broader healthcare and market commentary pieces referenced JNJ as a defensive Dividend Aristocrat, but these were mostly general background items rather than company-specific catalysts. Article Title
• Negative Sentiment: Recent coverage also noted that JNJ had slipped in the prior session, suggesting some near-term profit-taking even as longer-term fundamentals remain intact. Article Title

Johnson & Johnson Trading Down 1.9%

Johnson & Johnson stock opened at $258.48 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a market cap of $622.22 billion, a PE ratio of 29.88, a price-to-earnings-growth ratio of 2.58 and a beta of 0.24. The stock has a 50-day moving average of $236.47 and a two-hundred day moving average of $232.88. Johnson & Johnson has a one year low of $154.80 and a one year high of $269.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts anticipate that Johnson & Johnson will post 11.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Analysts Set New Price Targets

Several research firms have recently commented on JNJ. Johnson Rice set a $270.00 price target on Johnson & Johnson in a research report on Friday, June 26th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research note on Wednesday, April 15th. Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, June 15th. Royal Bank Of Canada restated an “outperform” rating and issued a $265.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 15th. Finally, Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $257.74.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.